This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2040 Remove Conditions Remove Treatment Related Topics
Clinical Trials Data Epilepsy Chronic Pain Concentrates Compliance Safety Cannabinoids Programs THC More Related Topics >
article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

OCTOBER 26, 2021

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic.

Pharmaceutical 52
Pharmaceutical Clinical Trials Research and Development Therapy 52
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

NOVEMBER 12, 2021

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. and Arjun Chanmugam, M.D., 19,985,645. .

Pharmaceutical 52
Pharmaceutical Clinical Trials Business Research and Development 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024